Teva- Pharmaceutical Industries Ltd
NYSE: TEVA
$16.43
-$0.32 (-1.9%)
Closing Price on November 15, 2024
TEVA Articles
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Published:
Last Updated:
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated:
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
Merrill Lynch has made many updates to its various lists, and one such list is the Top US Ideas for the first quarter of 2016.
Published:
Last Updated:
Which well-known and large cap stocks to do the major analysts on Wall Street like for 2016? Here are 10.
Published:
Last Updated:
These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current trading levels.
Published:
Last Updated:
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Published:
Last Updated:
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had a very hard time getting off the ground from 2011 through the start of 2014. This is the world’s top generic drug maker, and shares have...
Published:
Last Updated:
Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster timeline for repurchasing than most companies would give.
Published:
Last Updated:
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
Published:
Last Updated:
It is the best of both worlds for investors when large cap growth companies become inexpensive enough to have a value call.
Published:
Last Updated:
With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.
Published:
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Published:
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Published: